![glp-1 litigation Victoza Lawsuit [2026 Update] Evaluating Causation and Damages in](https://www.torhoermanlaw.com/wp-content/uploads/2021/07/Victoza-Lawsuit-Victoza-Lawsuit-Overview-Torhoerman-Law.jpg)
glp-1 litigation Victoza Lawsuit [2026 Update] Evaluating Causation and Damages in
Description
Health Promot Int
![glp-1 litigation Victoza Lawsuit [2026 Update] Evaluating Causation and Damages in](https://images.ctfassets.net/xp6aywb61p26/6G9cgFSbzrgO3iA1mh4oTG/0f181f270dcfcc8a9cfa07ccc8fd46a5/Evaluating_Causation_and_Damages_in_GLP-1_Drug_Lawsuits.png)
[DOI] [PMC free article] [PubMed] [Google Scholar] 200.Cusi K, Orsak B, Bril F, et al
![glp-1 litigation Victoza Lawsuit [2026 Update] Evaluating Causation and Damages in](https://lookaside.fbsbx.com/lookaside/crawler/media/?media_id=1355132583323881)
In a secondary analysis of this study, adjunctive liraglutide resulted in clinically significant weight loss and improvement in cognitive function
![glp-1 litigation Victoza Lawsuit [2026 Update] Evaluating Causation and Damages in](https://proassurance.com/hs-fs/hubfs/iStock-2189405678.jpg?width=300&name=iStock-2189405678.jpg)
The approval is backed by data from Part 1 of the Phase III RUBY trial, where treatment with the Jemperli regimen led to a 31% reduction in risk of death compared to chemotherapy alone
![glp-1 litigation Victoza Lawsuit [2026 Update] Evaluating Causation and Damages in](https://images.law.com/assets/36/2f/83b793d94af1a8764f6b9f72c971/wegovy-jpeg767x505.jpg)
